Demonstrated to significantly reduce stroke compared to warfarin, Pradaxa is first new oral anticoagulant approved by the FDA in more than 50 years RIDGEFIELD, Conn., Oct. 20 /PRNewswire/ -- The U.S.

“The results we have seen from RE-DUAL PCI™ are another great piece of evidence on the benefit Pradaxa ® can offer patients with atrial fibrillation and their treating physicians; a benefit which has ...

Dr. Noel G. Boyle, Professor of Medicine, Ronald Reagan UCLA Medical Center, Los Angeles, talks about new medications that can work as alternatives to warfarin for atrial fibrillation patients who are ...

WASHINGTON (March 19, 2017) -- Uninterrupted treatment with dabigatran, a non-vitamin K antagonist oral anticoagulant (NOACs), before, during and after ablation to treat atrial fibrillation ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. The parallel, open-label GIRAF trial randomly assigned ...

When it comes to preserving cognitive function in older patients with atrial fibrillation (AF) or flutter, the choice of oral anticoagulant doesn’t appear to matter much, according to the randomized ...

The anticoagulant medication dabigatran yielded similar results to warfarin for the prevention of cognitive decline in older adults with atrial fibrillation after two years of treatment, according to ...

Alembic has received the Food and Drug Administration’s permission for Dabigatran Etexilate Capsules, 75 mg and 150 mg and tentative approval for Dabigatran Etexilate Capsules, 110 mg. The approved ...

As expected, the European Medicines Agency (EMA) has extended the indications for the oral anticoagulant dabigatran (Pradaxa, Boehringer Ingelheim) to include treatment of deep vein thrombosis (DVT) ...

Three Groups Uncover New Gene Variants Affecting Heart Function Three separate research groups have identified a number of new genetic variants that influence heart rate and cardiac conduction. Two of ...